Deutsche Bank AG Makes New Investment in Aclaris Therapeutics, Inc. $ACRS

Key Points

• Deutsche Bank acquired 1,040,955 shares of Aclaris Therapeutics in the second quarter, valued at about $5.5 million and representing roughly 0.75% of the company. Institutional investors collectively own 98.34% of Aclaris.
• Aclaris reported quarterly revenue of $1.63 million and an EPS loss of $0.15, slightly beating analyst estimates, but continued to post substantial losses with a negative net margin of 921.50%.
• Analyst sentiment is broadly positive, with a consensus “Buy” rating and an average price target of $11.50, compared with the stock’s reported price of $6.31.

Deutsche Bank AG purchased a new stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,040,955 shares of the biotechnology company's stock, valued at approximately $5,507,000. Deutsche Bank AG owned about 0.75% of Aclaris Therapeutics at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. R Squared Ltd acquired a new stake in Aclaris Therapeutics in the 4th quarter valued at about $37,000. Strs Ohio acquired a new position in Aclaris Therapeutics during the first quarter worth approximately $60,000. CIBC Asset Management Inc acquired a new position in Aclaris Therapeutics during the fourth quarter worth approximately $52,000. China Universal Asset Management Co. Ltd. bought a new stake in Aclaris Therapeutics in the fourth quarter valued at approximately $53,000. Finally, Walleye Capital LLC bought a new stake in Aclaris Therapeutics in the second quarter valued at approximately $104,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Stock Performance

NASDAQ:ACRS opened at $6.31 on Tuesday. Aclaris Therapeutics, Inc. has a 52 week low of $1.74 and a 52 week high of $6.51. The firm has a market cap of $882.26 million, a price-to-earnings ratio of -10.88 and a beta of 0.78. The firm's 50-day simple moving average is $5.51 and its 200 day simple moving average is $4.51.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The firm had revenue of $1.63 million during the quarter, compared to the consensus estimate of $1.38 million. Sell-side analysts anticipate that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ACRS. Lifesci Capital assumed coverage on Aclaris Therapeutics in a research report on Tuesday, June 2nd. They issued an "outperform" rating and a $13.00 price objective for the company. Guggenheim assumed coverage on Aclaris Therapeutics in a report on Tuesday, May 5th. They set a "buy" rating and a $12.00 target price on the stock. Piper Sandler increased their price target on Aclaris Therapeutics from $7.00 to $11.00 and gave the company an "overweight" rating in a research note on Tuesday, May 5th. Wall Street Zen raised Aclaris Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, May 16th. Finally, Wedbush lifted their price objective on shares of Aclaris Therapeutics from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 29th. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Aclaris Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $11.50.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc NASDAQ: ACRS is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company's pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source